Trethera's Dual-Threat Drug Aims to Conquer Cancer and Autoimmunity

LOS ANGELES, CA – February 12, 2026 – In an ambitious move that could reshape treatment paradigms, Los Angeles-based Trethera Corporation is advancing a single drug, TRE-515, designed to combat both cancer and autoimmune diseases. The clinical-stage biopharmaceutical company is set to showcase the drug's significant clinical momentum at the upcoming 16th Annual Biocom Global Partnering and Investor Conference, signaling a pivotal transition from early-stage research to broader clinical expansion.

Fueled by a successfully completed Phase 1 trial and crucial designations from the U.S. Food and Drug Administration (FDA), Trethera is positioning TRE-515 as a 'pipeline-in-a-product.' This strategy hinges on the drug's unique ability to target a fundamental metabolic pathway that fuels the growth of abnormal cells across a spectrum of otherwise distinct medical conditions. The presentation, scheduled for February 24th in La Jolla, California, will be a key moment for the company as it seeks to attract the strategic partnerships and investment necessary to realize its expansive vision.

A 'Pipeline-in-a-Product' Strategy

At the heart of Trethera's strategy is the novel mechanism of its lead candidate, TRE-515. As a first-in-class, orally administered inhibitor of deoxycytidine kinase (dCK), the drug targets a critical vulnerability in rapidly proliferating cells. The dCK enzyme is a gatekeeper for the nucleoside salvage pathway, one of two routes cells use to produce the DNA building blocks (deoxyribonucleoside triphosphates, or dNTPs) necessary for replication.

In many aggressive cancers and during the inflammatory flare-ups of autoimmune diseases, abnormal cells become highly dependent on this salvage pathway to support their uncontrolled growth and survival. Healthy adult cells, in contrast, typically rely less on this pathway. By selectively blocking dCK, TRE-515 aims to starve diseased cells of their essential fuel for replication, leading to their demise while largely sparing healthy tissue. This shared metabolic dependency is the scientific foundation for Trethera's ambitious plan to develop a single therapeutic for multiple, diverse indications.

This approach challenges the traditional 'one drug, one disease' model of pharmaceutical development. “The potential for TRE-515 to treat a broad spectrum of diseases creates a pipeline-in-a-product approach that reduces overall development risk,” said Dr. Ken Schultz, Trethera Chairman and CEO, in a recent statement. The company, founded by prominent UCLA scientists, is leveraging this strategy to explore TRE-515's potential in conditions ranging from prostate cancer to neurologic autoimmune disorders, and even inflammatory bowel disease.

Clinical Momentum and Regulatory Validation

Trethera's presentation at Biocom is underpinned by a series of significant clinical and regulatory milestones. The company recently announced the successful completion of the dose-escalation portion of its Phase 1 solid tumor trial (NCT05055609), a critical step in establishing the drug's safety and determining the right dose for future studies.

Across 33 dosed patients with various solid tumors, TRE-515 was found to be well-tolerated. An independent safety committee reported no dose-limiting toxicities, even at the highest tested daily dose of 1,440 mg. This favorable safety profile allowed some heavily pre-treated patients to remain on therapy for over 300 days.

Beyond safety, the trial provided compelling early evidence of clinical activity. Disease control was observed in 47% of evaluable patients, with some achieving stable disease for extended periods. Crucially, biomarker data, including PET imaging and plasma analysis, confirmed that TRE-515 was successfully engaging its target, dCK, within the patients' bodies. These results have paved the way for the next phase of development, focusing on indication-specific trials.

Bolstering this clinical progress are two key FDA designations that could significantly accelerate TRE-515's path to market:

• Fast Track Designation for Prostate Cancer: This designation is designed to expedite the development and review of drugs for serious conditions with unmet medical needs. It provides Trethera with more frequent communication with the FDA and the possibility of a rolling review, potentially shortening the approval timeline for TRE-515 in combination with other therapies for metastatic castration-resistant prostate cancer.

• Orphan Drug Designation for Autoimmune Diseases: TRE-515 has also received Orphan Drug status for two rare autoimmune neurologic diseases, optic neuritis and acute disseminated encephalomyelitis (ADEM). This designation provides powerful incentives, including seven years of market exclusivity upon approval, tax credits for clinical trials, and waived FDA fees. These benefits make the development of therapies for rare diseases more economically viable, de-risking this arm of Trethera's dual-pronged strategy.

Targeting the Global Stage for Partnerships

The Biocom conference represents a strategic convergence of Trethera's scientific progress and its business objectives. The event is a premier forum for deal-making in the life sciences, attracting hundreds of institutional investors and senior executives from leading global pharmaceutical and biotechnology firms. For a privately held company like Trethera, this is a prime opportunity to secure the capital and collaborations needed to fund larger, more complex clinical trials.

“Completing oncology dose escalation was a pivotal milestone that positions Trethera to advance parallel clinical development efforts and efficiently expand patient trials,” Dr. Schultz noted. “This conference comes at an ideal time as Trethera transitions from dose finding to indication expansion and the next phase of clinical growth.”

The company's narrative is compelling: a first-in-class asset with a validated mechanism, a strong safety profile, early signs of efficacy, significant regulatory support from the FDA, and a robust intellectual property portfolio with patents potentially extending through 2045. By presenting this complete package at Biocom, Trethera is not just sharing data; it is making a clear case for its value and potential to prospective partners and investors, aiming to catalyze the next stage of its corporate and clinical journey.